The Alexandria Seed Capital Platform is an innovative funding model that brings together leaders from the life science community to catalyze early-stage investment in cutting-edge companies.

The platform’s preeminent Advisory Board consists of seasoned executives from biopharma and venture capital who evaluate seed-stage com- panies for potential future investment and help identify key near-term target milestones.

Led by Alexandria Venture Investments (AVI), the Advisory Board consists of representative members from AbbVie, Accelerator Life Science Part- ners, ARCH Venture Partners, Atlas Venture, Eli Lilly, Hatteras Venture Partners, Novartis, Pappas Capital, Pfizer, and Roche.

Deeply experienced in building and nurturing life science companies, Advisory Board members offer strategic guidance to entrepreneurs who receive funding through the platform. This high level of engagement is designed to increase the trajectory of our seed-stage recipient companies and to lay a foundation for future investment and collaboration.

Eligible Companies

Seed-stage companies are sourced directly from Alexandria’s national network, which includes Alexandria LaunchLabs member companies. Sec- tors of interest include novel drug discovery platforms, diagnostics, and next-generation research tools. Funding decisions are made based on the quality and differentiation of a company’s technology and foundational IP as well as on the strength of its business strategy, financing plan, and management team.

APPLY NOW

Selection Criteria

Funding decisions are made based on the quality and differentiation of a company’s technology, foundational IP, business strategy, financing plan, and management team.

Beyond Investment

Alexandria’s unique platform aims to enhance the momentum of early-stage life science investing and also to attract new interest from investors, both traditional and non-traditional, to opportunities in an industry that holds the promise of transformative discoveries in biomedicine.